In a letter to the World Health Organization (WHO) in which the Society shares concerns and recommendations, the ISSCR states, "As the WHO Expert Advisory Committee continues refining the draft framework, we encourage you to consider a few recommendations to ensure that genome editing technologies are adequately evaluated by regulators and proven safe and effective before being marketed to patients.

In response to the proposed €5 billion cut to the Horizon Europe budget, the ISSCR President Christine Mummery released the following statement…

Letters Cite Detrimental Affects to Scientific Advancement and Global Competitiveness

The ISSCR joined scientific societies in a joint letter to The White House and U.S. Administration officials citing grave concerns that the latest proposed Immigration and Customs Enforcement (ICE) action will cost the U.S. the current cohort of future innovators now enrolled in U.S. schools. The letter goes on to say the policy change could permanently destroy one of America’s main competitive advantages…

Misleading Marketing Preys on the Hopes of Patients and Families, Including Those with COVID-19

Skokie, IL – In letters released today by the International Society for Stem Cell Research (ISSCR) to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), the Society presses for greater enforcement to help protect patients suffering from devastating diseases including COVID-19.